ESSA Pharma Inc. filings document the company's completed plan of arrangement, shareholder approval process, capital-structure treatment of common shares, options and warrants, and subsequent Form 25 removal of its common stock from Nasdaq listing and Section 12(b) registration. Form 8-K reports cover material agreements, votes of securityholders, acquisition or disposition completion, governance matters, risk factors, clinical or regulatory disclosures, and operating and financial results.
ESSA Pharma Inc. (EPIX) released additional proxy-soliciting materials (DEFA14A) describing a Business Combination Agreement dated 13 July 2025 under which Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, will acquire all outstanding ESSA common shares via a British Columbia court-approved plan of arrangement.
Consideration: Each shareholder will receive (i) a cash payment equal to ESSA’s net cash at 12:01 a.m. Vancouver time on closing, less a US$4 million transaction fee, liabilities reserve and expenses, divided by outstanding shares (the “Cash Amount”), and (ii) one non-transferable contingent value right (CVR). The CVR could pay up to (a) US$2.8 million minus legal costs incurred within 18 months and (b) US$150 000 minus additional liabilities. Management currently estimates the combined initial distribution and closing cash at ≈US$1.90 per share, exclusive of any CVR proceeds.
- In-the-money options and warrants will be cashed out for the Cash Amount minus exercise price plus one CVR; all options are expected to be out-of-the-money at closing and will be cancelled without payment.
- ESSA will delist from Nasdaq and deregister under the U.S. Exchange Act; the company will also seek to cease reporting in British Columbia, Alberta and Ontario.
- A special meeting to vote on the arrangement must occur on or before 8 September 2025; closing is targeted for 2H 2025 and within three business days of the final court order.
- Deal failure would leave shareholders without consideration, while ESSA would continue to pursue a wind-up and could owe a US$2.5 million termination fee.
- Registered shareholders may exercise dissent rights; U.S. and Canadian tax summaries, meeting logistics and detailed procedures will appear in the forthcoming circular.
Key risks: completion uncertainty, variable cash amount, non-transferable CVRs, delisting/loss of future upside, and litigation or regulatory delays.